Literature DB >> 27587382

Remissions after long-term use of romiplostim for immune thrombocytopenia.

Ariela L Marshall1, Roberta Scarpone2, Melanie De Greef3, Robert Bird4, David J Kuter2.   

Abstract

Entities:  

Keywords:  immune thrombocytopenic purpura; platelets; romiplostim; thrombopoietin

Mesh：

Substances：

Year:  2016        PMID： 27587382      PMCID： PMC5479599          DOI： 10.3324/haematol.2016.151886

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  15 in total

Review 1.  Immune thrombocytopenic purpura.

Authors:  Douglas B Cines; Victor S Blanchette
Journal:  N Engl J Med       Date:  2002-03-28       Impact factor: 91.245

2.  AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP.

Authors:  James B Bussel; David J Kuter; James N George; Robert McMillan; Louis M Aledort; George T Conklin; Alan E Lichtin; Roger M Lyons; Jorge Nieva; Jeffrey S Wasser; Israel Wiznitzer; Reggie Kelly; Chien-Feng Chen; Janet L Nichol
Journal:  N Engl J Med       Date:  2006-10-19       Impact factor: 91.245

3.  Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group.

Authors:  Francesco Rodeghiero; Roberto Stasi; Terry Gernsheimer; Marc Michel; Drew Provan; Donald M Arnold; James B Bussel; Douglas B Cines; Beng H Chong; Nichola Cooper; Bertrand Godeau; Klaus Lechner; Maria Gabriella Mazzucconi; Robert McMillan; Miguel A Sanz; Paul Imbach; Victor Blanchette; Thomas Kühne; Marco Ruggeri; James N George
Journal:  Blood       Date:  2008-11-12       Impact factor: 22.113

Review 4.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.

Authors:  Cindy Neunert; Wendy Lim; Mark Crowther; Alan Cohen; Lawrence Solberg; Mark A Crowther
Journal:  Blood       Date:  2011-02-16       Impact factor: 22.113

5.  Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.

Authors:  Tomás José González-López; Cristina Pascual; María Teresa Álvarez-Román; Fernando Fernández-Fuertes; Blanca Sánchez-González; Isabel Caparrós; Isidro Jarque; María Eva Mingot-Castellano; José Angel Hernández-Rivas; Mónica Martín-Salces; Laura Solán; Paola Beneit; Reyes Jiménez; Silvia Bernat; Marcio M Andrade; Montserrat Cortés; Maria José Cortti; Susana Pérez-Crespo; Marta Gómez-Núñez; Pavel E Olivera; Gloria Pérez-Rus; Violeta Martínez-Robles; Rafael Alonso; Angeles Fernández-Rodríguez; María Carmen Arratibel; María Perera; Carmen Fernández-Miñano; Miguel Angel Fuertes-Palacio; Juan Andrés Vázquez-Paganini; Isabel Gutierrez-Jomarrón; Inés Valcarce; Erik de Cabo; Adriana Sainz; Rosa Fisac; Carlos Aguilar; María Paz Martínez-Badas; María Jesús Peñarrubia; María Calbacho; Carmen de Cos; Manuel González-Silva; Erika Coria; Arancha Alonso; Alberto Casaus; Armando Luaña; Pilar Galán; Cristina Fernández-Canal; Javier Garcia-Frade; José Ramón González-Porras
Journal:  Am J Hematol       Date:  2015-01-16       Impact factor: 10.047

Review 6.  Thrombopoietin: the primary regulator of platelet production.

Authors:  K Kaushansky
Journal:  Blood       Date:  1995-07-15       Impact factor: 22.113

7.  Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study.

Authors:  Adrian Newland; Bertrand Godeau; Victor Priego; Jean-Francois Viallard; María F López Fernández; Amelia Orejudos; Melissa Eisen
Journal:  Br J Haematol       Date:  2015-11-05       Impact factor: 6.998

8.  Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial.

Authors:  David J Kuter; James B Bussel; Roger M Lyons; Vinod Pullarkat; Terry B Gernsheimer; Francis M Senecal; Louis M Aledort; James N George; Craig M Kessler; Miguel A Sanz; Howard A Liebman; Frank T Slovick; J Th M de Wolf; Emmanuelle Bourgeois; Troy H Guthrie; Adrian Newland; Jeffrey S Wasser; Solomon I Hamburg; Carlos Grande; François Lefrère; Alan Eli Lichtin; Michael D Tarantino; Howard R Terebelo; Jean-François Viallard; Francis J Cuevas; Ronald S Go; David H Henry; Robert L Redner; Lawrence Rice; Martin R Schipperus; D Matthew Guo; Janet L Nichol
Journal:  Lancet       Date:  2008-02-02       Impact factor: 79.321

Review 9.  Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production.

Authors:  Diane Nugent; Robert McMillan; Janet L Nichol; Sherrill J Slichter
Journal:  Br J Haematol       Date:  2009-05-14       Impact factor: 6.998

10.  Feasibility of romiplostim discontinuation in adult thrombopoietin-receptor agonist responsive patients with primary immune thrombocytopenia: an observational retrospective report in real life clinical practice.

Authors:  Monica Carpenedo; Silvia Cantoni; Veronica Coccini; Marilena Fedele; Enrica Morra; Enrico Maria Pogliani
Journal:  Hematol Rep       Date:  2015-02-24
View more
  5 in total

1.  Updated international consensus report on the investigation and management of primary immune thrombocytopenia.

Authors:  Drew Provan; Donald M Arnold; James B Bussel; Beng H Chong; Nichola Cooper; Terry Gernsheimer; Waleed Ghanima; Bertrand Godeau; Tomás José González-López; John Grainger; Ming Hou; Caroline Kruse; Vickie McDonald; Marc Michel; Adrian C Newland; Sue Pavord; Francesco Rodeghiero; Marie Scully; Yoshiaki Tomiyama; Raymond S Wong; Francesco Zaja; David J Kuter
Journal:  Blood Adv       Date:  2019-11-26

2.  Cost-effectiveness of second-line therapies in adults with chronic immune thrombocytopenia.

Authors:  George Goshua; Pranay Sinha; Natalia Kunst; Lauren Pischel; Alfred Ian Lee; Adam Cuker
Journal:  Am J Hematol       Date:  2022-02-11       Impact factor: 13.265

3.  Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.

Authors:  Indraraj Umesh Doobaree; Adrian Newland; Vickie McDonald; Raghava Nandigam; Lesley Mensah; Sandrine Leroy; Anouchka Seesaghur; Hitan Patel; Sally Wetten; Drew Provan
Journal:  Eur J Haematol       Date:  2019-03-07       Impact factor: 2.997

4.  Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method.

Authors:  Adam Cuker; Jenny M Despotovic; Rachael F Grace; Caroline Kruse; Michele P Lambert; Howard A Liebman; Roger M Lyons; Keith R McCrae; Vinod Pullarkat; Jeffrey S Wasser; David Beenhouwer; Sarah N Gibbs; Irina Yermilov; Michael S Broder
Journal:  Res Pract Thromb Haemost       Date:  2020-12-08

5.  Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations.

Authors:  Monica Carpenedo; Erminia Baldacci; Claudia Baratè; Alessandra Borchiellini; Francesco Buccisano; Giuseppina Calvaruso; Federico Chiurazzi; Bruno Fattizzo; Gaetano Giuffrida; Elena Rossi; Francesca Palandri; Potito Rosario Scalzulli; Sergio Mario Siragusa; Angelantonio Vitucci; Francesco Zaja
Journal:  Ther Adv Hematol       Date:  2021-10-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.